



Published in final edited form as:

Laryngoscope. 2019 August ; 129(8): 1763–1771. doi:10.1002/lary.27863.

3D-printed, externally-implanted, bioresorbable airway splints for severe tracheobronchomalacia

Andrea S. Les, PhD^a, Richard G. Ohye, MD^b, Amy G. Filbrun, MD^c, Maryam Ghadimi Mahani, MD^d, Colleen L. Flanagan, MS^a, Rodney C. Daniels, MD^e, Kelley M. Kidwell, PhD^f, David A. Zopf, MD, MS^a, Scott J. Hollister, PhD^g, Glenn E. Green, MD^a

^aDepartment of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI

^bDepartment of Cardiac Surgery, University of Michigan, Ann Arbor, MI

^cDepartment of Pediatric Pulmonology, University of Michigan, Ann Arbor, MI

^dDepartment of Radiology, University of Michigan, Ann Arbor, MI

^eDepartment of Pediatrics, Division of Critical Care Medicine, University of Michigan, Ann Arbor, MI

^fDepartment of Biostatistics, University of Michigan, Ann Arbor, MI

^gDepartment of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA

Abstract

Objective—To report the clinical safety and efficacy of 3D-printed, patient-specific, bioresorbable airway splints in a cohort of critically ill children with severe tracheobronchomalacia.

Methods—From 2012–2018, 15 subjects received 29 splints on their trachea, right and/or left mainstem bronchi. The median age at implantation was eight months (range, 3–25 months). Nine children were female. Five subjects had a history of ECMO (extra-corporeal membrane oxygenation), and eleven required continuous sedation, six of which required paralytics to maintain adequate ventilation. Thirteen were chronically hospitalized, unable to be discharged, and seven were hospitalized their entire lives. At the time of splint implantation, one subject required ECMO, one required positive airway pressure, and 13 subjects were tracheostomy and ventilator dependent, requiring a median positive end-expiratory pressure (PEEP) of 14 cmH₂O (range, 6–20 cmH₂O). Outcomes collected included level of respiratory support, disposition, and splint-related complications.

Results—At the time of discharge from our institution, at a median of 28 days' post-implantation (range, 10–56 days), the subject on ECMO was weaned from extracorporeal support, and the subjects who were ventilated via tracheostomy had a median change in PEEP (discharge – baseline) of –2.5 cmH₂O (range, –15 to 2 cmH₂O, p=0.022). At median follow-up of 8.5 months (range, 0.3–77 months), all but one of the 12 surviving subjects lives at home. Of the 11 survivors

who were tracheostomy dependent pre-op, one is decannulated, one uses a speaking valve, six use a ventilator exclusively at night, and three remain ventilator dependent.

Conclusion—This case series demonstrates the initial clinical efficacy of the 3D-printed bioresorbable airway splint device in a cohort of critically ill children with severe tracheobronchomalacia.

Keywords

Tracheobronchomalacia; splint; 3D-printing; critical care; airway

Introduction

Tracheobronchomalacia is a condition of dynamic collapse of the trachea or bronchi during respiration. Diagnosis is typically made via bronchoscopy. Mild forms manifest as a cough, wheeze, or impaired secretion clearance. Severe forms have reported mortality rates up to 80%¹. Tracheobronchomalacia can be idiopathic or associated with prematurity, genetic cartilaginous or other syndromes, congenital cardiovascular anomalies, or tracheoesophageal fistulas^{2,3}.

Current therapies for severe tracheobronchomalacia include tracheostomy with prolonged mechanical ventilation⁴, aortopexy⁵, tracheobronchopexy^{1,6}, and intraluminal metallic^{7,8}, silicone⁹, or bioresorbable^{10–12} stents. However, these options carry a significant risk of morbidity and mortality, variable efficacy, and a subset of children still suffer acute life-threatening events despite these interventions. In one study of 47 children with tracheobronchomalacia hospitalized in an intensive care setting, 28 (60%) died³.

For all but severe cases, if a child can be supported for 24 months, natural airway growth and maturation resolves symptoms⁴. We have developed a 3D printed, externally implanted, bioresorbable airway splint that provides luminal support for at least two years, and is subsequently resorbed, obviating the need for surgical removal. Results of the first patient¹³, and then the first three patients were reported previously¹⁴; here we report clinical outcomes of all 15 children who received splints at our institution through July 2018.

Materials and Methods

Patient Selection

Only children who were at high risk of death or permanent disability were considered for airway splinting. This included life-threatening events associated with tracheobronchomalacia, mechanical ventilation requiring prolonged sedation, and airway erosion. Cross-disciplinary consultation was utilized to ensure that airway splinting did not constitute futile care. Children were not excluded for tracheobronchomalacia distal to the areas able to be splinted, severe concomitant pulmonary/cardiovascular disease, ECMO status, or underlying cartilaginous disorders. While tracheobronchomalacia is more frequently characterized by circumferential collapse due to weakness of the anterior (cartilaginous) airway, it can also be caused by intrusion of the posterior (membranous)

airway. Patients were not excluded based upon type of tracheobronchomalacia. Patients with only one lung were also not excluded.

Splint Design, Manufacturing Process, and Regulatory Process

The splint design and fabrication process has been detailed previously^{15,16}. Briefly, pre-operative inspiratory/expiratory computed tomography (CT) and bronchoscopy were performed to confirm the diagnosis and location of tracheobronchomalacia. Inspiratory and expiratory patient airway models are generated from CT data using Mimics Innovation Suite (Materialise NV, Leuven, Belgium) to determine malacic segment length and diameter; splint designs are then automatically generated from this input data with Custom MATLAB (MathWorks, Natick, Massachusetts) code, and subsequently test fit on the patient models. Splints were then 3D printed from 96% polycaprolactone/4% hydroxyapatite via laser sintering, and sterilized via ethylene oxide (Nelson Laboratories, Salt Lake City Utah).

Permission from the Food and Drug Administration (FDA) and our institutional review board (IRB) was obtained for each case via the FDA Expanded Access pathway (“compassionate use”). Informed consent was obtained from each patient’s parent or guardian.

Surgical Technique

Pre-operative bronchoscopy is performed to evaluate the airway. A median sternotomy with or without a cervical incision is performed. The anterior and lateral aspects of the trachea and/or mainstem bronchi were isolated and the area(s) of malacia are confirmed. After choosing the splint(s) of best fit, a series of partial thickness polypropylene sutures are placed circumferentially around the malacic segment(s). The sutures were then passed through the interstices of the splint, and the splints are parachuted down on to the airways. The sutures were then tied, suspending the trachea/bronchi within the splint. Surgical clips denoted proximal and distal ends of the splints for radiographic studies. If the child required concomitant cardiac repair, this was completed after splint implantation. Intra-operative bronchoscopy confirmed patency of the splinted regions.

Data Collection

For the duration of the study, parents and referring physicians were queried for clinical updates. Once patients surpassed 1-year after implantation, families were invited to enroll in a formal survey study to collect information about hospitalizations, illnesses, or adverse events. Separate IRB approval and research consent were obtained for this study.

Statistical analysis

Respiratory variables, length of hospitalization, age at implantation, and length of follow-up were collected. For this series of 15 patients, data is descriptive and reported as medians and ranges. For the 12 patients with positive end-expiratory pressure (PEEP) measurements both pre-operative and at discharge from our institution, and the nine with PEEP measurements at last follow-up (i.e. on positive pressure ventilation), differences were calculated and the median change was compared to zero via the sign test. McNemar’s test compared pre- to

post-surgical numbers of patients with chronic hospitalization and ECMO or continuous ventilation for the 12 patients with both measures. The cumulative incidence function of the time (months) to discontinuation of daytime mechanical ventilation was estimated and plotted using an unadjusted Fine-Gray model¹⁷ in the presence of competing risks (death).

Results

From February 2012 - July 2018, twenty-nine splints were implanted in 15 children. Median age at implantation was eight months (range, 3–25 months). Nine children were female. The median follow-up was 8.5 months (range, 0.3–77.1 months). Implanted splints included ten (35%) tracheal, twelve (41%) left mainstem bronchus (LMB) and seven (24%) right mainstem bronchus (RMB) splints. The left main bronchus was more commonly splinted than the right, secondary to an increased incidence of vascular compression. 10 children had splints implanted in more than one location. The average sizes of the tracheal, LMB, and RMB splints were (inner diameter × length in mm): 13.3 × 21.2, 8.7 × 13.0, and 9.4 × 9.1, respectively.

Co-morbidities and indications for airway splinting are presented in Table 1. The primary indication for splinting was cardiopulmonary life-threatening events in 12 patients (including five with a history of ECMO), life-threatening tracheostomy tube erosion and failure to wean from mechanical ventilation in one patient, failure to wean from mechanical ventilation in one patient, and social factors necessitating avoidance of a tracheostomy in one patient. All patients had previous surgical attempts to address tracheobronchomalacia and all but one was tracheostomy and ventilator dependent. Eleven patients required sedation to maintain adequate ventilation, and of those, six also required paralytics. Thirteen patients were hospitalized in an intensive care setting prior to transfer to our institution, unable to be discharged home, and seven had been hospitalized their entire life. Six patients were born before 37 weeks' gestation. Two children had congenital absence of the right lung and had previously undergone long-segment slide tracheoplasties for tracheal stenosis.

All 15 patients had intrathoracic tracheobronchomalacia, and a median sternotomy was performed, ten of which were re-sternotomies. Two patients also had tracheobronchomalacia that extended proximally to the tracheostomy stoma, and a cervical incision was also performed. Three patients had solely or predominantly posterior tracheobronchomalacia.

Cardiopulmonary bypass is not required for splint placement, except as indicated for cardiorespiratory instability. Bypass was used during splint placement in the first five patients and for only one of ten subsequent patients. One child had splints placed while on ECMO. Eight patients had cardiac or vascular defects that were addressed during the same surgery immediately after splint placement. Age and year of implantation, and pre-op clinical status is presented in Table 2. No patient required splint removal or re-operation for their splint(s).

Pre-operatively, all but one patient were tracheostomy and ventilator dependent, requiring a median PEEP of 14 cmH₂O (range, 6–20 cmH₂O). Of the 13 patients discharged from our institution who were initially ventilator dependent, one no longer required mechanical

ventilation, while the median PEEP for the remaining 12 was 8 cmH₂O (range, 5–14 cmH₂O) at a median of 28 days post-op (range, 10–56 days). For the 12 patients with pre-op and discharge PEEP measures, discharge PEEP levels were significantly lower, with a median change from discharge to pre-op of –2.5 cmH₂O (range –15 to 2, p=0.022). In total, 12 patients were transferred back to the referring institution, two were discharged home, and one died prior to discharge. At a median follow-up of 8.5 months (range 0.3–77 months), 12 patients are long-term survivors and all but one (a recent case) live at home. For the nine patients who still have a tracheostomy at last follow-up, PEEP values (daytime) continued to decrease with a median change from most recent to pre-op of –8 cmH₂O (range –14 to –2 cmH₂O, p=0.004). A summary of pre-operative and post-operative clinical outcomes are listed in Tables 2 and 3. At last follow-up, of the 12 survivors, one patient remains hospitalized, and only three require continuous mechanical ventilation (Figure 1). Median time to discontinuation of daytime mechanical ventilation (or cumulative incidence of time to daytime ventilator discontinuation in the presence of competing risks (death), Figure 2) is 12.0 months. Severe lobar and/or segmental malacia (distal to mainstem bronchi) was a common finding in children unable to discontinue ventilator support.

Serial magnetic resonance imaging (MRI) was performed in Case 1. The MRIs demonstrated intact splint at six and 12 months post-op, but evidence of degradation at 38 and 49 months post-op (Figure 3). Representative pre-op and post-op minimum intensity projection generated images from the expiratory CT scans are presented in Figure 4.

No child required removal or replacement of their splint(s). As of July 2018, the first four children to receive splints are more than two years past splint implantation; all are alive with sustained significant clinical benefit. One child later required an aortopexy 2.5 years after splint implantation and subsequent discharge home due to moderate malacia distal to the splinted region.

Complications

Among the 15 patients receiving 29 splints, there were two complications related to surgical dissection. One entry into the tracheoesophageal fistula repair pouch occurred and was closed primarily. During another dissection, the trachea and mainstem bronchi were both entered at multiple sites due to the extremely thin airway wall, associated with the patient's underlying Meier-Gorlin syndrome. This resulted in two dehiscences, which continue to heal while the patient remains on oral antibiotics.

There were three mortalities. Two patients died with patent airways due to non-splint-related causes. One patient died seven months after implantation after suffering an arrest secondary to diffuse hemoptysis, a rare, but known complication of single ventricle anatomy¹⁸. An autopsy confirmed the presence of many prominent congested submucosal vessels and abnormal dilated tortuous veins well away from the splints. A second patient died 10 days' post-op with airways that were patent in the splinted region, after suffering an arrest secondary to CO₂ retention and acidosis, complicated by reactive pulmonary hypertension related to parenchymal disease in her single lung.

One patient died of a possible splint-related complication from upper gastrointestinal hemorrhage 6-months post-op. Post-mortem evaluation revealed that the tracheal splint was displaced from its original position and eroded into the esophagus. The patient's other splint was in its expected location. She was also found to have gastric erosions. Autopsy was not able to define the source of the hemorrhage.

Length of Hospitalizations

Median length of hospitalization prior to transfer to our institution was 113 days (range, 0 to 501 days). Seven patients were hospitalized their entire lives prior to transfer to our institution. Median length of hospitalization at our institution was 45 days (range, 12 to 72 days), with the first 14 days occupied by medical assessment and designing, manufacturing, and sterilizing the airway splints for patients who were chronically hospitalized (n=13) and unable to wait at home during splint manufacture. Two patients were discharged directly home from our institution at a median of 23 days (range, 11–35 days) following implantation. For the ten patients who were discharged from their referring institution after back-transfer from our institution, the median length of hospitalization at the referring institution was 62 days (range, 1 to 285 days). The median total length of hospitalization from splint implantation to discharge home for the twelve patients who survived and were discharged was 73 days (range, 11–315 days).

Discussion

The severity of pediatric tracheobronchomalacia varies widely. The diagnosis of TBM is often suspected based on clinical signs and symptoms such as an expiratory wheeze that simulates recalcitrant asthma. However, these clinical findings are neither sensitive nor specific. Endoscopic evaluation remains the gold standard for diagnosis, with flexible bronchoscopy during spontaneous breathing being preferred. In general, >50% narrowing of the airway is accepted as diagnostic of tracheomalacia, but classification of severity beyond that remains subjective and ill-defined^{19,20}. In addition to diagnostic bronchoscopy, contrast expiratory/inspiratory CT can aid in identifying specific regions of collapse, degree of distal malacia, and any vascular anomalies^{21,22}.

Children with mild TBM typically become asymptomatic after age two, often with no intervention required. Moderate cases can be treated conservatively with pharmacotherapy, including low dose inhaled ipratropium or bethanachol, along with chest physiotherapy to improve secretion clearance and treatment of respiratory infections. Moderate-to-severe cases may be managed with continuous positive airway pressure (CPAP) to provide a distending pressure to the airways and prevent collapse on exhalation. More severe cases often present with recurrent pneumonias requiring hospitalization, inability to extubate following illness or procedures, or life-threatening events. These cases may require surgical intervention, which includes aortopexy, tracheobronchopexy, or tracheostomy with or without mechanical ventilation.

A tracheostomy with or without mechanical ventilation is the most common treatment for moderate-severe tracheobronchomalacia. The tracheostomy tube can bypass proximal tracheomalacia and can stent open the mid-trachea. A ventilator can then deliver positive

pressure to pneumatically stent open the more distal airways. This treatment provides respiratory support until the child can outgrow their malacia as the airway enlarges and the cartilage in their airways strengthens ^{2,4}. Complications such as delay in initiation of oral feedings ²³, developmental delay, and delay in speech and language development have been reported, along with sudden death at home ^{4,23}. In one study of 32 premature infants and 18 full-term infants with tracheobronchomalacia, a tracheotomy was required in 24 (75%) of the pre-term and seven (39%) of the full-term infants ⁴. In these patients, CPAP was used in the management of all of the premature patients and in three (43%) of the seven full-term infants with a tracheotomy ⁴. The average duration of CPAP was 21.4 months for the premature infants and 22.0 months for the full-term infants. There were three deaths in the series.

For the most severe cases, tracheostomy with mechanical ventilation even at extremely high PEEP is often inadequate. In the current study, out of the 14 children with a tracheostomy pre-op, 12 were experiencing cardiopulmonary life-threatening events despite mechanical ventilation and high levels of PEEP.

Standard anterior aortopexy is commonly used to treat moderate-severe tracheobronchomalacia. Aortopexy entails suturing the ascending aorta or aortic arch to the posterior aspect of the sternum. Due to the approximation of the anterior tracheal wall and posterior aorta, this surgery may improve tracheal patency. A meta-analysis of 581 children who received aortopexy for tracheobronchomalacia found that 80% showed significant clinical improvement, 8% showed no improvement, 4% had a worsening of their symptoms and 6% died at a median follow-up of 47 months ⁵. However, aortopexy has a high failure rate, particularly for severe cases such as the patients in our series.

Others have tried posterior aortopexy—suturing the descending aorta to the thoracic vertebrae—to address left mainstem bronchomalacia. Unfortunately, in the largest study of this technique, 8 out of 18 of children were found to have residual severe left mainstem bronchomalacia requiring a tracheostomy (n=1) or placement of internal stents (n=7) ²⁴.

Jennings has pioneered tracheobronchopexy, in which the posterior (membranous) trachea is sutured to the anterior spinal ligament and/or the anterior (cartilaginous) trachea and/or bronchi are sutured to the sternum. In a recent case series, authors report no early or late deaths ⁶. A two-stage approach is often required, as is mobilization of the esophagus. While the technique appears to be efficacious in the trachea and right mainstem bronchus, left mainstem bronchomalacia was relieved in only two out of seven cases ⁶. In contrast our external splint has been equally effective for the trachea, and both mainstem bronchi. In addition, in comparison to our cohort, the patients who receive tracheobronchopexy were less critically ill than our cohort. In a later case series by the same group, 13% of their patients had apparent life-threatening events pre-operatively, considerably less than our cohort, of which 86% had documented cardiopulmonary life-threatening events ²⁵.

In cases where tracheostomy with mechanical ventilation has failed or is contraindicated, other experimental treatments such as bioresorbable, silicone, and metallic stenting ⁷⁻¹² have been utilized, with varying degrees of success. Internal stenting for tracheobronchomalacia

carries significant risk of device migration and obstruction of the airway with silicone stents⁹, and formation of granulation tissue with resultant airway obstruction with metallic stents²⁶. Bioresorbable internal stents may require serial stenting and involves careful surveillance due to the short resorption time and possible device migration¹⁰.

Various forms of external splinting have been attempted for severe tracheobronchomalacia refractory to traditional supportive treatment^{27,28}. As early as 1968, ribs were used to externally splint the trachea^{29,30}. In the late 1970s through the 1980s, Filler and colleagues used a silicone elastomer (Slastic) reinforced polypropylene mesh (Marlex) splint which was applied externally to the airways with mixed results^{28,31–33}. More recently, groups in Germany and Japan described techniques to treat pediatric tracheobronchomalacia via external airway stabilization using polytetrafluoroethylene (PTFE) prostheses^{27,34}. Specifically, Ando et al. reported 98 patients undergoing 127 external PTFE airway stents at a mean age of 7.2 months²⁷. In this series, there were 14 deaths (14%), including six (6%) that were possibly or definitely device-related, with twelve patients (12%) requiring re-operations, nine for restenosis and three for removal due to perforation of the airway. In comparison, we report three deaths (20%) in our cohort, one of which was possibly device-related (7%), but in a more severe clinical population compared to the PTFE series (86% vs. 37% with documented cardiopulmonary life-threatening events). No patient in our cohort required splint reoperation.

Limitations of present study

This is a non-randomized case series with historical data for comparison of outcomes. All patients were medically complex, with significant co-morbidities and prior cardiac, airway, and other interventions. In some cases, concurrent cardiac repair was performed. These factors may confound determining the influence of our device on clinical outcomes. The extent to which the data can be extrapolated to a less critically ill patient population is unknown.

Conclusion

The study presents the clinical results of 15 patients treated with 3D-printed, patient-specific, externally-implanted, bioresorbable airway splints. The overall device-related complication and mortality rates were low in this population of critically ill, medically-complex patients. All surviving patients experienced significant clinical benefit. A pivotal clinical trial is planned in pursuit of FDA approval and subsequent broader application.

Acknowledgments

Funding and Conflict of Interest

This work was funded in part by the NIH under Award Number UL1TR002240, UL1TR00043, and 1U01TR002488. This work was also funded in part by NIH grants R21 HD076370 and R01 HD086201 (to S.J.H. and G.E.G.). Device development was funded by NIH grant UL1 RR024986 and FDA grant P50 FD003787. We gratefully acknowledge the support of the Michigan Institute for Clinical and Health Research (MICHCR) IND/IDE Investigator Assistance Program (MIAP) for their Expanded Access regulatory support.

Dr Green and Dr Hollister are co-inventors on an airway splint patent assigned to the Regents of the University of Michigan. This patent has been licensed by the University of Michigan to Materialise NV, Leuven, Belgium. The

University, Dr Green, and Dr Hollister could benefit financially if and when the airway splint is commercialized. The other authors have no financial relationships relevant to this article to disclose.

References

1. Mitchell ME, Rumman N, Chun RH, et al. Anterior tracheal suspension for tracheobronchomalacia in infants and children. *Ann Thorac Surg*. 2014;98(4):1246–1253. [PubMed: 25086944]
2. Carden KA, Boiselle PM, Waltz DA, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults: an in-depth review. *Chest*. 2005;127(3):984–1005. [PubMed: 15764786]
3. Burden RJ, Shann F, Butt W, Ditchfield M. Tracheobronchial malacia and stenosis in children in intensive care: bronchograms help to predict outcome. *Thorax*. 1999;54(6):511–517. [PubMed: 10335005]
4. Jacobs IN, Wetmore RF, Tom LW, Handler SD, Potsic WP. Tracheobronchomalacia in children. *Arch Otolaryngol Head Neck Surg*. 1994;120(2):154–158. [PubMed: 8297572]
5. Torre M, Carlucci M, Speggorin S, Elliott MJ. Aortopexy for the treatment of tracheomalacia in children: review of the literature. *Ital J Pediatr*. 2012;38:62. [PubMed: 23110796]
6. Bairdain S, Smithers CJ, Hamilton TE, et al. Direct tracheobronchopexy to correct airway collapse due to severe tracheobronchomalacia: Short-term outcomes in a series of 20 patients. *J Pediatr Surg*. 2015;50(6):972–977. [PubMed: 25824437]
7. Filler RM, Forte V, Chait P. Tracheobronchial stenting for the treatment of airway obstruction. *J Pediatr Surg*. 1998;33(2):304–311. [PubMed: 9498407]
8. Valerie EP, Durrant AC, Forte V, Wales P, Chait P, Kim PC. A decade of using intraluminal tracheal/bronchial stents in the management of tracheomalacia and/or bronchomalacia: is it better than aortopexy? *J Pediatr Surg*. 2005;40(6):904–907; discussion 907. [PubMed: 15991168]
9. Fayon M, Donato L, de Blic J, et al. French experience of silicone tracheobronchial stenting in children. *Pediatr Pulmonol*. 2005;39(1):21–27. [PubMed: 15532081]
10. Vondry D, Elliott MJ, McLaren CA, Noctor C, Roebuck DJ. First experience with biodegradable airway stents in children. *Ann Thorac Surg*. 2011;92(5):1870–1874. [PubMed: 22051281]
11. Anton-Pacheco JL, Luna C, Garcia E, et al. Initial experience with a new biodegradable airway stent in children: Is this the stent we were waiting for? *Pediatr Pulmonol*. 2016;51(6):607–612. [PubMed: 26584412]
12. Serio P, Fainardi V, Leone R, et al. Tracheobronchial obstruction: follow-up study of 100 children treated with airway stenting. *Eur J Cardiothorac Surg*. 2014;45(4):e100–109. [PubMed: 24446473]
13. Zopf DA, Hollister SJ, Nelson ME, Ohye RG, Green GE. Bioresorbable airway splint created with a three-dimensional printer. *N Engl J Med*. 2013;368(21):2043–2045. [PubMed: 23697530]
14. Morrison RJ, Hollister SJ, Niedner MF, et al. Mitigation of tracheobronchomalacia with 3D-printed personalized medical devices in pediatric patients. *Sci Transl Med*. 2015;7(285):285ra264.
15. Hollister SJ, Flanagan CL, Zopf DA, et al. Design control for clinical translation of 3D printed modular scaffolds. *Ann Biomed Eng*. 2015;43(3):774–786. [PubMed: 25666115]
16. Morrison RJ, Hollister SJ, Niedner MF, et al. Mitigation of tracheobronchomalacia with 3D-printed personalized medical devices in pediatric patients (Supplementary Material). *Sci Transl Med*. 2015;7(285):285ra264.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94(446):496–509.
18. Averin K, Byrnes JW, Bencotter DT, et al. Life-threatening airway bleeding after palliation of single ventricle congenital heart disease. *Heart*. 2017.
19. Hysinger EB. Laryngomalacia, Tracheomalacia and Bronchomalacia. *Curr Probl Pediatr Adolesc Health Care*. 2018;48(4):113–118. [PubMed: 29622320]
20. Hysinger EB, Panitch HB. Paediatric Tracheomalacia. *Paediatr Respir Rev*. 2016;17:9–15. [PubMed: 25962857]
21. Lee EY, Boiselle PM. Tracheobronchomalacia in infants and children: multidetector CT evaluation. *Radiology*. 2009;252(1):7–22. [PubMed: 19561247]

22. Lee EY, Mason KP, Zurakowski D, et al. MDCT assessment of tracheomalacia in symptomatic infants with mediastinal aortic vascular anomalies: preliminary technical experience. *Pediatr Radiol.* 2008;38(1):82–88. [PubMed: 18038169]
23. Wiseman NE, Duncan PG, Cameron CB. Management of tracheobronchomalacia with continuous positive airway pressure. *J Pediatr Surg.* 1985;20(5):489–493. [PubMed: 3903098]
24. Arcieri L, Serio P, Nenna R, et al. The role of posterior aortopexy in the treatment of left mainstem bronchus compression. *Interact Cardiovasc Thorac Surg.* 2016;23(5):699–704. [PubMed: 27382044]
25. Bairdain S, Zurakowski D, Baird CW, Jennings RW. Surgical Treatment of Tracheobronchomalacia: A novel approach. *Paediatr Respir Rev.* 2016;19:16–20. [PubMed: 27237407]
26. Food and Drug Administration. Safety Warning: Metallic Tracheal Stents in Patients with Benign Airway Disorders. 2005; <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm153009.htm>.
27. Ando M, Nagase Y, Hasegawa H, Takahashi Y. External stenting: A reliable technique to relieve airway obstruction in small children. *J Thorac Cardiovasc Surg.* 2017;153(5):1167–1177. [PubMed: 28242014]
28. Filler RM, Buck JR, Bahoric A, Steward DJ. Treatment of segmental tracheomalacia and bronchomalacia by implantation of an airway splint. *J Pediatr Surg.* 1982;17(5):597–603. [PubMed: 7175652]
29. Vasko JS, Ahn C. Surgical management of secondary tracheomalacia. *Ann Thorac Surg.* 1968;6(3):269–272. [PubMed: 4917593]
30. Johnston MR, Loeber N, Hillyer P, Stephenson LW, Edmunds LH Jr. External stent for repair of secondary tracheomalacia. *Ann Thorac Surg.* 1980;30(3):291–296. [PubMed: 7425707]
31. Blair GK, Cohen R, Filler RM. Treatment of tracheomalacia: eight years' experience. *J Pediatr Surg.* 1986;21(9):781–785. [PubMed: 3534208]
32. Vinograd I, Filler RM, Bahoric A. Long-term functional results of prosthetic airway splinting in tracheomalacia and bronchomalacia. *J Pediatr Surg.* 1987;22(1):38–41. [PubMed: 3819991]
33. Filler RM, Messineo A, Vinograd I. Severe tracheomalacia associated with esophageal atresia: results of surgical treatment. *J Pediatr Surg.* 1992;27(8):1136–1140; discussion 1140–1131. [PubMed: 1403550]
34. Hagl S, Jakob H, Sebening C, et al. External stabilization of long-segment tracheobronchomalacia guided by intraoperative bronchoscopy. *Ann Thorac Surg.* 1997;64(5):1412–1420; discussion 1421. [PubMed: 9386713]




Figure 1:

The number of patients who were chronically hospitalized and who had continuous mechanical ventilation (or ECMO) pre- versus post-op. (ECMO, extracorporeal membrane oxygenation). The number of top of the bar is the frequency. Note 15 children are included pre-op and 12 post-op. * indicates that $p < 0.01$.




Figure 2. The cumulative incidence function of the time (months) to discontinuation of daytime mechanical ventilation using an unadjusted Fine-Gray model in the presence of competing risks (death). Seven children were able to discontinue daytime mechanical ventilation within a year of airway splint implantation.

Splint Degradation by Serial MRI




Figure 3.

In serial MRIs of patient 1, the splint is represented by a signal void surrounding the left main bronchus. The splint is intact at 6 months' and 12 months' post-op, but shows evidence of degradation at 38 months and 49 months. The yellow star indicates the lumen of the unsplinted RMB. The blue star indicates the lumen of the splinted LMB. (MRI, magnetic resonance imaging; RMB, right mainstem bronchus; LMB, left mainstem bronchus).




Figure 4.

The location of malacia has varied between patients, as shown in the above minimum intensity projections generated from the pre-operative (left) and post-operative (right) expiratory CT scans. Patient 5 had severe tracheobronchomalacia, Patient 10 had complete expiratory collapse of the mid-trachea (red arrow) (10A), and Patient 13 had paracarinal malacia and right mainstem bronchomalacia (red arrow). All improved on post-splint images

(5B, 10B, and 13B). All images were acquired with the tracheostomy tube removed except for image 13B.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1:

Indications for Splint Implantation

Case	Co-morbid Diagnoses	Indications for splint implantation, history of:			
		ECMO	Cardio-pulmonary arrest requiring compressions	Bag-mask ventilation	Other
1	Criss-cross branch pulmonary arteries, moderate hypoplasia of RPA, tortuous ascending aorta, born at 35-weeks' gestation		Yes	Yes	
2	s/p TOF/APV repair, 22q11 Deletion, renal tubular acidosis, protein-losing enteropathy			Yes	
3	s/p TOF/APV repair and tracheal stenosis resection, failure to thrive	Yes		Yes	
4	s/p hypoplastic arch reconstruction and PAB placement, s/p takedown of PAB and VSD closure, residual VSD, SubAS, chromosomal abnormality		Yes	Yes	
5	s/p TOF/APV repair, 22q11 Deletion syndrome, s/p metallic bronchial stent placement	Yes	Yes	Yes	
6	s/p aortopexy		Yes	Yes	
7	HLHS, s/p Norwood, s/p H-type tracheoesophageal fistula repair	Yes	Yes	Yes	
8	Complete AVSD, dextrocardia, heterotaxy with polysplenia, anomalous systemic and pulmonary venous return, pulmonary artery stenosis, s/p pacemaker placement for heart block				Unable to wean off ventilator. In need of complex cardiac repair.
9	s/p congenital diaphragmatic hernia repair, VSD, s/p PDA ligation, pulmonary hypertension, tracheal erosion in region of innominate, born at 35-weeks gestation				Tracheal erosion caused by long-term mechanical ventilation.
10	Born at 26 weeks gestation, bronchopulmonary dysplasia, pulmonary hypertension, grade I IVH.			Yes	
11	s/p congenital diaphragmatic hernia repair, right lung agenesis, pulmonary hypertension, long segmental tracheal stenosis s/p slide tracheoplasty. Born at 36+6/7 weeks gestation.	Yes		Yes	
12	Meier-Gorlin syndrome		Yes	Yes	
13	Unrepaired TOF/APV, PKU embryopathy, micrognathia, microcephaly, horseshoe kidney, cleft palate, s/p laryngotracheal reconstruction. Born at 36 weeks.		Yes	Yes	
14	Right lung agenesis, long-segment tracheal stenosis s/p slide tracheobronchoplasty, and s/p aortopexy	Yes		Yes	
15	Chronic lung disease, multiple ventricular septal defects s/p repair, mitral stenosis, hypoplastic aortic arch with coarctation of the aorta s/p repair. Born at 29 weeks gestation.			Yes	Desire to avoid a tracheostomy due to social and logistical concerns.

Table 2:

Age and year of implantation, and pre-operative status of the splint patients

Patient	Age at Implantation (months)	Year of Implantation	Respiratory Status	PEEP (cmH ₂ O)	Pre-op Status			Living Situation
					Required sedation to maintain ventilation?	Required paralytics to maintain ventilation?	Predominantly posterior malacia?	
1	3	2012	Trach and vent dependent	14	Continuous	Yes	No	PICU for 1.5 months
2	16	2014	Trach and vent dependent	20	Continuous	Yes	No	NICU/PICU for entire life (16 months)
3	5	2014	Trach and vent dependent	10	Continuous	No	No	PICU for 3 months
4	10	2015	Trach and vent dependent	10	Continuous	Yes	No	PICU for 2 months
5	5	2016	Trach and vent dependent	14	Continuous	Yes	No	NICU/PICU for entire life (5 months)
6	4	2016	Trach and vent dependent	16	Continuous	No	No	NICU/PICU for 3 months
7	8	2016*	Trach and vent dependent	10	Continuous	No	Yes	NICU/PICU for entire life (8 months)
8	25	2017*	Trach and vent dependent	6	No	No	No	Home, previous long hospitalizations
9	16	2017	Trach and vent dependent	14	No	No	No	Home, previous long hospitalizations
10	9	2017	Trach and vent dependent	14	Continuous	No	Yes	NICU/PICU for entire life (9 months)
11	6	2017*	Trach and vent dependent	14	Continuous	No	No	PICU for 2 months
12	6	2018	Trach and vent dependent	18	Continuous	Yes	No	NICU/PICU for entire life (6 months)
13	11	2018	Trach and vent dependent	14	No	No	Yes	Hospitalized entire life (11 months)
14	4	2018	Trach and vent dependent, on ECMO at the time of splint implantation	On ECMO	Continuous	Yes	No	NICU/PICU entire life (4 months)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Pre-op Status								
Patient	Age at Implantation (months)	Year of Implantation	Respiratory Status	PEEP (cmH ₂ O)	Required sedation to maintain ventilation?	Required paralytics to maintain ventilation?	Predominantly posterior malacia?	Living Situation
15	13	2018	HFNC during the day, CPAP at night.	8 (CPAP mask at night)	No	No	No	Hospitalized for 4 months

Table 3:

Post-operative status of the splint patients

Status as of July 2018 (Post-op)					
Patient	Respiratory Status	Current PEEP (cmH ₂ O)	Required sedation to maintain ventilation?	Required paralytics to maintain ventilation?	Current Disposition
1	Speaking valve all day	Day 0; Night: 0	No	No	Home
2	Decannulated	None	No	No	Home
3	Trach dependent. Vent dependent at night only	Day: 0; Night: 8	No	No	Home
4	Trach dependent. Vent dependent at night only	Day 0; Night: 6	No	No	Home
5	Trach and vent dependent	10	No	No	Home
6	Trach dependent. Vent dependent at night only	Day: 0; Night: 8	No	No	Home
7	Died 6.8 months post-op with patent airways. Cause: underlying congenital heart disease	N/A	Before terminal decline, no	Before terminal decline, no	Deceased
8	Died 6 months post-op with patent airways. Cause: upper gastrointestinal hemorrhage	N/A	Before death, no	Before death, no	Deceased
9	Trach dependent. Vent dependent at night only	Day 0; Night: 6	No	No	Home
10	Trach dependent. Vent dependent at night only	Day: 0; Night: 8	No	No	Home
11	Died at 10 days post-op with patent airways. Cause: underlying parenchymal (single) lung disease	N/A	Prior to death, yes	Prior to death, yes	Deceased
12	Trach and vent dependent	6	No	No	Home
13	Trach dependent. Vent dependent at night only	Day 0; Night: 6	No	No	Home
14	Trach and vent dependent	14 (weaning)	Yes, weaning	No	PICU
15	Nasal cannula during the day and night	None	No	No	Home